Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Improved Reliability of the Rapid Microtiter Plate Assay Using Recombinant Enzyme in Predicting CYP2D6 Inhibition in Human Liver Microsomes

Leonard V. Favreau, Jairam R. Palamanda, Chin-chung Lin and Amin A. Nomeir
Drug Metabolism and Disposition April 1999, 27 (4) 436-439;
Leonard V. Favreau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jairam R. Palamanda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chin-chung Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amin A. Nomeir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A higher throughput method of screening for the inhibition of recombinant CYP2D6 using a microtiter plate (MTP) assay was evaluated using 62 new chemical entities and compared to data from the dextromethorphan O-demethylase assay in human liver microsomes (HLM). The IC50 values for the two assays closely matched for 53 compounds (85%). Six of the variant nine compounds had higher IC50 values with the recombinant enzyme, whereas three had lower IC50 values with the recombinant enzyme. When the inhibition with the recombinant enzyme was determined at various time points, the IC50 values increased as the duration of the incubation increased for the six compounds with higher IC50 values in the MTP assay. The IC50 values at 10 min matched more closely the IC50 values in HLM (95% compared with 85%). For three compounds that showed comparable IC50 values in the two assays, and the three compounds with lower IC50 values in the MTP assay, the IC50 values did not change over time. These results suggest that the six compounds that showed higher IC50 values in the MTP assay at 45 min are substrates for CYP2D6. Using known CYP2D6 substrates, a similar phenomenon was observed, i.e., inhibition curves shifted to higher IC50values as incubation time increased. These results indicate that the higher throughput MTP assay is more comparable to HLM if the IC50 values are determined at 10 min rather than the recommended 45 min. Furthermore, data acquisition at multiple time points may indicate if a compound is a potential substrate or metabolism/mechanism-based inhibitor for the enzyme.

Xenobiotics are primarily oxidatively metabolized in the liver by a family of heme-containing enzymes, namely cytochrome P-450 (Gonzalez, 1989). In human liver, the five isoforms that are primarily responsible for the metabolism of most drugs include CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 (Guengerich, 1995). It has been reported that CYP2D6 represents only 2% of total liver cytochrome P-450, although it is involved in the metabolism of 30% of marketed drugs (Shimada et al., 1994; Guengerich, 1996; Lewis et al., 1997). Therefore, it is important to evaluate the inhibition potential of new chemical entities (NCEs)1for CYP2D6 early in the discovery stage to avoid potential drug-drug interaction.

Recently, a 96-well microtiter plate (MTP) assay using microsomes from recombinant baculovirus-infected insect cells expressing a single cytochrome P-450 (Supersomes) has been reported (Crespi et al., 1997). The MTP assay is rapid, reproducible, and inexpensive, whereas the assessment of CYP2D6 inhibition in human liver microsomes (HLM) is much more time consuming. Our laboratory has used this method to estimate the IC50 values for CYP2D6 and compared them to values obtained for the inhibition of dextromethorphanO-demethylase activity in HLM using conventional HPLC techniques. We have compared the IC50 values obtained by both methods for a series of 62 structurally related NCEs and found that the values for 53 compounds were similar in both assays (Palamanda et al., 1998). For the other nine compounds, the IC50 values differed by 6- to 93-fold in both assays. The present study was initiated to address the differences between the two assays observed for these nine compounds. The objective was to minimize the discrepancy between the two methods and therefore reduce the number of false negatives and/or false positives.

Materials and Methods

Source of Chemicals.

Human liver microsomes were obtained from the International Institute for the Advancement of Medicine (Exton, PA). The microsomes were thawed, pooled, aliquoted, and refrozen at −80°C before use. Insect cell microsomes containing cDNA-expressed CYP2D6-Val (Supersomes) were obtained from Gentest Corporation (Woburn, MA). Quinidine, dextromethorphan, and β-NADPH were purchased from Sigma Chemical Company (St. Louis, MO). Imipramine, trifluperidol, and propranolol were purchased from ICN Biomedicals (Aurora, OH). The substrate for the MTP assay, 3-cyano-7-ethoxycoumarin and its metabolite, 3-cyano-7-hydroxycoumarin, were obtained from Molecular Probes, Inc. (Eugene, OR). Pluronic F-68 was purchased from Life Technologies (Gaithersburg, MD). NCEs for the enzyme inhibition studies were synthesized at Schering-Plough Research Institute as part of a drug discovery program.

Enzyme Assays.

The dextromethorphan O-demethylase assay for CYP2D6 in HLM was performed according to a modification of a previously published method (Chen et al., 1990; Palamanda et al., 1998). Initial studies in our laboratory have established a Km of approximately 18 μM. The substrate concentration used in the inhibition studies is 16 μM, which approximates theKm. Also, it is estimated that the reaction mixture contains 1 pmol of CYP2D6. Metabolite production was quantified by comparison to a standard curve of known concentrations of dextrorphan.

The microtiter plate assay for CYP2D6 was performed with a CytoFluor Series 4000 Multi-well Plate Reader (PerSeptive Biosystems, Framingham, MA) according to Crespi et al. (1997) with modifications. All compounds for analysis were initially dissolved in methanol. Stock solutions were made in 20% aqueous methanol and the final methanol concentration in the assay was 0.5%. A 20 mM 3-cyano-7-ethoxycoumarin solution was prepared in acetonitrile. After the addition of 5 μl of the test compound, 95 μl of a 100 mM potassium phosphate buffer, pH 7.4, containing 3 mM β-NADPH, 0.02% Pluronic F-68 (a nonionic surfactant of polyoxyethylene-polyoxypropylene copolymer used to help solubilize the substrate), and 100 μM 3-cyano-7-ethoxycoumarin, was added to each well. The plate was preincubated at 37°C for 5 min, then 100 μl of a 100 mM potassium phosphate buffer, pH 7.4, containing 50 pmol/ml of insect cell-expressed CYP2D6-Val (Supersomes) was added. Therefore, the reaction mixture contained 5 pmol CYP2D6 as reported byCrespi et al. (1997). Initial studies in our laboratory have shown that the Km for 3-cyano-7-ethoxycoumarin was 45 μM, similar to a Km of 67 μM reported by Crespi et al. (1997). The final substrate concentration used was 50 μM, which approximates the Km. The plate was incubated for 45 min at 37°C followed by the addition of 100 μl of a reaction-stop solution containing 60% acetonitrile and 40% 0.1 M Tris, pH 9. In some experiments, after the addition of the recombinant enzyme to start the reaction, fluorescence data were acquired every 10 min for 50 min by scanning while the plate remained in the instrument.

Data Analysis.

Relative CYP2D6 activity was calculated from the fluorescence data for each time point using CytoCalc Data Analysis Software (PerSeptive Biosystems, Framingham, MA). The IC50 values were estimated by comparison to control values, i.e., enzyme in the reaction mixture and 0.5% methanol.

Results and Discussion

We previously reported the IC50 values for 62 NCEs using Supersomes and human liver microsomes for CYP2D6 inhibition (Palamanda et al., 1998). Of these structurally related compounds, the IC50 values for the two assays closely matched for 53 of the 62 (85%) compounds (difference equal to or less than 5-fold). The remaining nine compounds had IC50 values in the MTP assay that differed from the IC50 values in HLM assay by more that 5-fold (compounds 54 to 62, Table 1). The IC50 values for six compounds were 9- to 28-fold higher in the MTP assay, whereas the IC50 values for the other three compounds were 6- to 93-fold higher in the HLM assay (Palamanda et al., 1998). A difference of 5-fold or less in the IC50 was considered acceptable because we were comparing data from a single cytochrome P-450 isoform (Supersomes) to data from a mixture of cytochrome P-450 enzymes (HLM) and the substrates were different. Also, literature IC50values for quinidine inhibition of CYP2D6 using dextromethorphan (Rodrigues and Roberts, 1997) and bufuralol (Halliday et al., 1995) as substrates were 0.22 μM and 0.04 μM, respectively, a difference of slightly over 5-fold. However, it should be noted that the [S]/Km ratios for the two reactions may be different, which could have contributed to the difference in the IC50 values. In our studies, the [S]/Km ratio was approximately 1 for both the MTP and HLM assays.

View this table:
  • View inline
  • View popup
Table 1

Comparison of the IC50 values from the human liver microsomes (HLM) assay and from selected time points in the MTP assay

To determine if the IC50 values observed at the 45-min endpoint in the MTP assay remained constant throughout the incubation, fluorescence data were acquired at 10, 30, and 50 min intervals. The IC50 values for the six compounds that showed higher IC50 in the MTP assay shifted markedly to higher values over time (compounds 54–59, Table 1), whereas the IC50 values for the three compounds that showed lower IC50 values in the MTP assay remained relatively stable (compounds 60–62, Table 1). Also, three additional compounds (compounds 18, 21, and 26; Table 1) whose IC50 values were within 5-fold of the IC50 values determined in HLM showed relatively stable IC50 (2- to 3-fold differences in the IC50 values; Table 1). Upon using the IC50 values observed at 10 min in the MTP assay, all but the three compounds that showed lower IC50 in the MTP assay were found to have IC50 values within a 5-fold difference from the HLM assay, i.e., 95% match (Table 1).

The higher IC50 values in the MTP assay at 45 to 50 min compared to 10 min for the six compounds suggest that the higher concentration of CYP2D6 and the longer incubation period in the MTP assay may be more rapidly inactivating the test compounds than in HLM. This is evident because the amount of CYP2D6 used in each assay and the duration of the incubation are different. In HLM, it is estimated that the concentration of CYP2D6 is 5 pmol/mg protein (Shimada et al., 1996). Under our assay conditions for HLM, i.e., 1 mg/ml microsomal protein and a 200 μl volume, there is 1 pmol enzyme present. In the MTP assay, 5 pmol enzyme per well (in 200 μl) are required due to the low turnover rate of the enzyme for the substrate (Crespi et al., 1997). The incubation times are 15 and 45 min for the HLM assay and the MTP assay, respectively. Therefore, in the MTP assay, there is 5 times more enzyme present and the length of the incubation is approximately 3 times longer than in the HLM assay; this may result in a more rapid metabolism in the MTP assay. This is consistent with our finding that for those six compounds that showed higher IC50values in the MTP assay at 45 to 50 min, the IC50at 10 min matched more closely with the IC50 in HLM. To confirm that the shift to higher IC50values over time is an indicator of metabolism, known substrates of CYP2D6 were tested (Spatzenegger and Jaeger, 1995). When dextromethorphan, imipramine, propranolol, and trifluperidol were evaluated in the MTP assay, the IC50 curves shifted to the right for all compounds, i.e., higher IC50 values over time (Fig.1). In contrast, when quinidine was analyzed, the IC50 value did not change over time. This is expected because quinidine is a competitive inhibitor of CYP2D6 but not a substrate (Nielson et al., 1995). Nevertheless, this hypothesis needs to be further confirmed by monitoring the reaction mixture by liquid chromatography-mass spectrometry analysis. Using this generalization, a shift of inhibition curves to theleft over time (i.e., lower IC50) would suggest metabolism- or mechanism-based inhibition. Because there are no known specific metabolism-based inhibitors of CYP2D6 (Parkinson, 1996), preliminary experiments were carried out with the MTP assay using recombinant CYP3A4 from baculovirus-infected insect cells as described by Crespi et al. (1997; data not shown). The inhibition curves for erythromycin and troleandomycin, both of which are mechanism-based inhibitors of CYP3A4, shifted to the left, i.e., lower IC50 values over time, whereas the curve for ketoconazole, a nonmechanism-based inhibitor of CYP3A4, remained relatively stable over time. Therefore, these observations may have general application in rapidly screening NCEs for inhibition of cytochrome P-450 enzymes.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Inhibition curves for dextromethorphan (A), propranolol (B), imipramine (C), trifluperidol (D), and quinidine (E) at selected time points in the MTP assay.

In comparing the results from the MTP assay to those obtained from CYP2D6 inhibition in HLM, it is important to point out that insect cell microsomes containing the expressed enzyme do not contain any other cytochrome P-450 isoforms. Thus, the potential for metabolism by any of the other cytochrome P-450 isoforms in liver microsomes does not exist in the Supersomes. If a compound is metabolized in HLM by one isoform to a less potent inhibitor for a second isoform, it is expected that its IC50 obtained with HLM would be higher than that obtained in the MTP assay. Therefore, it is reasonable to speculate that the three compounds with higher IC50 values in HLM might have been subjected to metabolism to less potent inhibitors by other cytochrome P-450 isoforms. However, it should be mentioned that using the recombinant CYP2D6 preparation results in a more intrinsically accurate estimate of the IC50 of a particular compound for this isoform, but may not reflect the apparent IC50determined in HLM, which is probably more relevant in predicting drug-drug interactions. Furthermore, in the prediction of the in vivo inhibition potential for of a specific cytochrome P-450 and the consequent clinically relevant drug-drug interaction, plasma levels (better yet concentrations in the liver) of the compound and the potency of the inhibitor (better expressed asKi) all must be taken into consideration.

Results of the current study indicate that the risk of overestimating the IC50 (false positive) for a test compound is minimized by using data acquired after shorter incubation time (10 min instead of 45 min). This results in increased predictability of the MTP from 85 to 95%. However, there is still a concern for the compounds that showed lower IC50 in the MTP assay (3 of 62, approximately 5%) because of the potential of discarding these three NCEs (false negatives). Nevertheless, in the final analysis, utilization of Supersomes coupled with the MTP technology has greatly helped us select appropriate NCEs quickly by enhancing throughput. This is a “balancing act” between discarding a small number of false negatives versus enhanced throughput, but the overall benefit derived by accelerating our discovery program outweighs the loss of approximately 5% of NCEs during the first supersomal screen.

In conclusion, the results of the present study demonstrate that the MTP assay using recombinant enzyme may be useful for screening large numbers of compounds for potential inhibition of CYP2D6. Furthermore, the IC50 values obtained at early time points in the MTP assay more closely predict the IC50values obtained in HLM assay. However, the IC50values of selected candidates should still be confirmed in HLM.

Acknowledgments

We thank Dr. Mitchell N. Cayen for reviewing the manuscript and providing valuable suggestions. We also thank Dr. Charles Ruegg and Dr, Paul Silber of In Vitro Technologies, Inc. for performing enzyme inhibition studies with some compounds.

Footnotes

  • Send reprint requests to: Dr. Amin A. Nomeir, Ph.D., Department of Drug Metabolism and Pharmacokinetics, Mail Stop 2880, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033. E-mail: Amin.Nomeir{at}spcorp.com

  • Abbreviations used are::
    NCE
    new chemical entity
    MTP
    microtiter plate
    HLM
    human liver microsomes
    • Received July 27, 1998.
    • Accepted January 18, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Chen ZR,
    2. Somogyi AA,
    3. Bochner F
    (1990) Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 12:97–104.
    OpenUrlPubMed
  2. ↵
    1. Crespi CL,
    2. Miller VP,
    3. Penman PW
    (1997) Microtiter plate assays for inhibition of human drug-metabolizing cytochromes P450. Anal Biochem 248:188–190.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Gonzalez F
    (1989) The molecular biology of cytochrome P450s. Pharmacol Rev 40:243–288.
    OpenUrlPubMed
  4. ↵
    1. Ortiz-de Montellano PR
    1. Guengerich FP
    (1995) Human cytochrome P450 enzymes. in Cytochrome P450, ed Ortiz-de Montellano PR (Plenum Press, New York), pp 473–535.
  5. ↵
    1. Guengerich FP
    (1996) In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 24:521–533.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Halliday RC,
    2. Jones BC,
    3. Smith DA,
    4. Kitteringham NR,
    5. Park BK
    (1995) An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 40:369–378.
    OpenUrlPubMed
  7. ↵
    1. Lewis DFV,
    2. Eddershaw PJ,
    3. Goldfarb PS,
    4. Tarbit MH
    (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27:319–340.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Nielson F,
    2. Rosholm JU,
    3. Brøsen K
    (1995) Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 48:501–504.
    OpenUrlPubMed
  9. ↵
    1. Palamanda JR,
    2. Favreau LV,
    3. Lin CC,
    4. Nomeir AA
    (1998) Validation of a rapid microtiter plate assay to conduct cytochrome P4502D6 enzyme inhibition studies. Drug Discovery Today 3:466–470.
    OpenUrlCrossRef
  10. ↵
    1. Parkinson A
    (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:45–57.
  11. ↵
    1. Rodrigues AD,
    2. Roberts EM
    (1997) The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos 25:651–655.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Shimada T,
    2. Yamazaki H,
    3. Mimura M,
    4. Inui Y,
    5. Guengerich FP
    (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes from 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Shimada T,
    2. Yamazaki H,
    3. Mimura M,
    4. Wakamiya N,
    5. Ueng YF,
    6. Guengerich FP,
    7. Inui Y
    (1996) Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 24:515–522.
    OpenUrlAbstract
  14. ↵
    1. Spatzenegger M,
    2. Jaeger W
    (1995) Clinical importance of hepatic cytochrome P450s in drug metabolism. Drug Metab Rev 27:397–417.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (4)
Drug Metabolism and Disposition
Vol. 27, Issue 4
1 Apr 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Improved Reliability of the Rapid Microtiter Plate Assay Using Recombinant Enzyme in Predicting CYP2D6 Inhibition in Human Liver Microsomes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

Improved Reliability of the Rapid Microtiter Plate Assay Using Recombinant Enzyme in Predicting CYP2D6 Inhibition in Human Liver Microsomes

Leonard V. Favreau, Jairam R. Palamanda, Chin-chung Lin and Amin A. Nomeir
Drug Metabolism and Disposition April 1, 1999, 27 (4) 436-439;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

Improved Reliability of the Rapid Microtiter Plate Assay Using Recombinant Enzyme in Predicting CYP2D6 Inhibition in Human Liver Microsomes

Leonard V. Favreau, Jairam R. Palamanda, Chin-chung Lin and Amin A. Nomeir
Drug Metabolism and Disposition April 1, 1999, 27 (4) 436-439;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communication

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics